Virginia Commonwealth University

VCU Massey Cancer Center

Suggested grant language

Investigators contemplating the inclusion of core laboratory services in a pending grant application are strongly encouraged to consult with the faculty core director in order to craft grant language tailored to a particular application, and to develop a suitable budget for the proposed services. However, as a starting place, the following language may be used as a template:

“The VCU Massey Cancer Center Transgenic/Knock-out Mouse Facility, established in 2000, provides a comprehensive suite of services for the creation of genetically modified mice. The facility, located [location redacted, enquire with core director] occupies ~1000 sq ft of space, including a 600 sq ft laboratory, a 150 sq ft tissue culture room, and a 250 sq ft animal holding room.  The facility is well-equipped (primary instrumentation includes a Olympus IX-71 inverted injection scope with DP-72 digital camera and stage cooling, Narishige micromanipulators, and a Celtram air microinjector), and offers the production of both transgenic and  knock-out or knock-in mice.  All stages of transgenic mouse production are offered, including consulting, creation of targeting vectors, ES cell electroporation, screening of ES cell clones, blastocyst injection, and breeding of chimeras.  In addition, the core laboratory also has extensive expertise in the mouse line re-derivation by embryo transfer, embryo and sperm cryopreservation, tail DNA preparation and genotyping. The core also maintains an IVIS spectrum imager for live animal imaging.  The core is directed by Dr. Jolene Windle, who has been actively involved in developing genetically engineered mouse models since 1986.  She is supported by Resource Manager Greg Campbell, who has worked with transgenic animals since 1996, Laboratory Specialist Jillian Stifflinger, and Research Associate Dr. Mark Subler.  The VCU Massey Cancer Center Transgenic/Knock-out Mouse Facilityis supported, in part, by funding from the NIH-NCI Cancer Center Support Grant P30 CA016059.”